Cytotoxic chemotherapy followed by hypofractionated radiotherapy to sensitize pancreatic cancer to immunotherapy consisting of combined PD-1 and CTLA4 blockade. The gene discussed is CTLA4; the disease is familial pancreatic carcinoma.